Reduces intraocular pressure (IOP). Sold as Vyzulta. Every FDA application for this active ingredient: 1 branded and 1 generic.
As of Nov 15, 2026, FDA lists 2 applications for Latanoprostene Bunod (sold as Vyzulta), first approved Nov 2, 2017, with 0 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Vyzulta | Part D | $136M | +6% | 79,708 |
| Nov 2, 2017 | VyzultaNDA 207795 · New molecular entity | Bausch And Lomb | 1 | Marketed |
| Apr 29, 2025 | Latanoprostene BunodANDA 217387 | Gland | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
